Imunon, Inc. - Common Stock IMNN 深 沪
等待开盘 12-30 09:30:00 美东时间
3.63
+0.480
+15.24%
华盛通- 最 高4.00
- 今 开3.12
- 成交量 29.98万股
- 最 低 2.99
- 昨 收 3.15
- 总市值 1114.56万
- 52周最高 41.2174
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 2.99
- 委 比 70.07%
- 总股本 307.04万
- 历史最高 25857.3851
- 量 比 5.61
- 振 幅 32.06%
- 历史最低 2.99
- 每 手 1
- 风险率 4.90%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Imunon (NASDAQ:IMNN) shares increased by 8.8% to $3.6 during Wednesday...
12-25 05:05
Earnings Scheduled For November 13, 2025
Companies Reporting Before The Bell • Edgewell Personal Care (NYSE:EPC) is proj...
11-13 19:11
IMUNON Updates on Final Phase 3 Trial for its DNA-Based Ovarian Cancer Therapy
IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today is presenting an update on recent progress with its IMNN-001 development program for the treatment of
11-10 20:44
IMUNON To Present Ongoing Phase 3 OVATION 3 Clinical Trial Of IMNN-001 At IGCS 2025 Annual Global Meeting
Trials-in-progress poster of ongoing pivotal Phase 3 trial of DNA-mediated immunotherapy accepted at both IGCS and ESMO Congress 2025
10-30 20:07
IMUNON to Present New Translational Data from Phase 2 OVATION 2 Study of IMNN-001 at SITC 40th Annual Meeting
IMUNON, Inc. is advancing its IMNN-001 therapy for advanced ovarian cancer, with new Phase 2 data to be presented at SITC 2025. The IL-12 DNA-based therapy shows improved survival and immune response in trials. The pivotal Phase 3 OVATION 3 trial is ongoing to confirm these results.
10-23 14:01
IMUNON Hosts R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer
IMUNON Inc. will host an R&D Day for investors on November 10, 2025, in New York City, to provide updates on its Phase 3 study of IMNN-001, a DNA-mediated immunotherapy for advanced ovarian cancer. Keynote speakers include ovarian cancer experts, principal investigators, and statistical experts, who will discuss the latest data and progress of the OVATION 3 Study. The event will also feature a live Q&A session and networking opportunities. IMUNON...
10-20 12:05
IMUNON Invited to Present PlaCCine® DNA Technology Proof-of-Concept Data in Platform Presentations at Leading Vaccine Conferences
IMUNON, Inc., a clinical-stage biotech company, is seeking strategic partners to advance its PlaCCine technology platform. The company will present IMNN-101, its investigational DNA plasmid vaccine, at two upcoming vaccine conferences, highlighting proof-of-concept clinical trial results. IMNN-101 demonstrated stronger durability of protection and immune response compared to mRNA vaccines, with no serious adverse effects reported. IMUNON aims to ...
10-17 12:10
IMUNON To Present Phase 3 OVATION 3 Clinical Trial IMNN-001 At ESMO Congress
Prestigious European Society for Medical Oncology Conference "trials-in-progress" sessionPivotal OVATION 3 trial of its DNA-mediated immunotherapy in newly diagnosed patients underwayCompany on track with established
10-14 20:21
IMUNON to Present Phase 3 Ovarian Cancer Study of IMNN-001 at ESMO Congress
<p>IMUNON, Inc. announced the acceptance of an abstract on its Phase 3 OVATION 3 trial for IMNN-001, a DNA-mediated IL-12 immunotherapy, for presentation at the European Society for Medical Oncology (ESMO) Congress 2025. IMNN-001, based on TheraPlas® technology, is designed to locally produce IL-12 in the tumor microenvironment, enhancing anti-cancer immunity. The trial is enrolling patients with newly diagnosed advanced ovarian cancer and has sh...
10-14 12:20
IMUNON Presents IMNN-001 Phase 2 Translational Data in Advanced Ovarian Cancer Demonstrating 13-Month OS Extension via Tumor Micro-Environment Shift
IMUNON announces positive results from its Phase 2 OVATION 2 Study for IMNN-001, an IL-12 immunotherapy for advanced ovarian cancer. The study highlights significant anti-cancer immune responses, improved overall survival, and a favorable safety profile. A pivotal Phase 3 trial (OVATION 3) is underway, with four trial sites activated and more being added to accelerate patient recruitment.
09-22 12:05
